Antibody-drug conjugates
Antibody-drug conjugates are one of the company’s stated oncology focuses.
Source: LinkedIn company description · Retrieved October 13, 2026
CIS BIOPHARMA designs targeted cancer therapies intended to act on tumor cells while minimizing harm to healthy tissue.
The company works with partners in oncology drug development.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
CIS BIOPHARMA identifies partners seeking to expand their oncology portfolios and investors seeking sustainable value in breakthrough science as audiences.
Antibody-drug conjugates are one of the company’s stated oncology focuses.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026, September 16, 2026, September 18, 2026, September 19, 2026, September 21, 2026, September 28, 2026, September 29, 2026 and October 8, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.